Posted by Michael Wonder on 02 Mar 2023
Santhera submits marketing authorisation application to the UK MHRA for vamorolone in Duchenne muscular dystrophy
1 March 2023 - Santhera Pharmaceuticals announces that it has submitted a marketing authorisation application to the UK MHRA for vamorolone for the treatment of Duchenne muscular dystrophy.
In parallel to the marketing authorisation application submission to the UK MHRA, Santhera is currently preparing an application to include vamorolone for the treatment of Duchenne muscular dystrophy in the Early Access to Medicines Scheme in the UK.
